MedTrace Logo

First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors

NCT04675996 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-02-08

No results posted yet for this study

Summary

This is a 2 part, multi-center, open-label, First-in-Human clinical study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of INT-1B3 in the treatment of patients with advanced solid tumors.

Conditions

Interventions

DRUG

INT-1B3

60-min i.v. infusions twice per week in 21-day cycles

Sponsors & Collaborators

  • InteRNA

    lead INDUSTRY

Principal Investigators

  • Roel Schaapveld, PhD · InteRNA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-18
Primary Completion
2023-03-24
Completion
2023-03-24

Countries

  • Belgium
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04675996 on ClinicalTrials.gov